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Pyrazine compounds are present in a variety of foods, beverages 
and pharmaceuticals. Various pyrazines are known to have antibacterial, 
antituberculosis, antidepressant, diuretic, anticonvulsant, pesticidal 
and herbicidal activity (1). Alkylpyrazine compounds are present in a 
variety of roasted foods and are responsible for many of the character-
istic flavors and odors of these foods. Beef, cocoa, potato and soybean 
products, coffee, tomatoes and peppers are but a few examples of foods 
that have been shown to contain pyrazine compounds (2). It has been 
suggested that these compounds are probably formed via complex reactions 
between alpha amino acids and carbohydrates (3). 
In recent years patents have been granted for the use of various 
pyrazines as flavor additives for food and tobacco products (4, 5, 6, 7, 
8, 9). In the near future meat substitutes, such as vegetable and 
"single cell" protein, coupled with flavor additives, are likely to 
play a key role in feeding the world's increasing population. Thus it 
is possible that pyrazine compounds may be consumed in larger amounts. 
Aside from their strong organoleptic properties mono- and dimethyl-
pyrazines are also central nervous system depressants having hypnotic 
and anticonvulsant activities. Of a series of pyrazines tested in this 
regard, Nishie et al. (10) have shown that 2,3-dimethylpyrazine has 
the strongest activity. Its hypnotic activity is one-thirteenth that 
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of sodium phenobarbital. Much work has been published on the presence 
of alkylpyrazines in various foods, but little on the metabolism of 
these compounds. In view of this, the objectives of this work are as 
follows: 
1) To synthesize and determine the toxicity of 2,3~dimethylpyrazine. 
2) To define to metabolic fate of the compound in a mammal; that is, 
to determine how fast and in what form(s) it is excreted. 
3) To localize the probable site of metabolism in the animal. 
4) To attempt to induce the metabolizing system and monitor any 




Pyrazines, or 1,4-diazines, are based on the six-membered pyrazine 
nucleus having two nitrogen atoms para to each other. There are two 
other classes of diazines. They are pyridazines and pyrimidines which 
have their two nitrogens situated ortho and meta, respectively. 
Pyrazine compounds are somewhat similar to their pyridine analogs 
in reactivity at their alpha carbon atoms. When compared to the pyri-
dines, they have a higher pi-electron density at the nitrogen atoms and 
lower electron density at the carbon atoms. The pKa of pyrazine is 
0.65. Compared to pyridine (5.2), pyridazine (2.33) and pyrimidine 
(1.30) it is noted that a second ring nitrogen has a strong base-
weakening effect and that the basicity varies inversely to the separa-
tion between the two nitrogens in the diazines (1). Each methyl group 
increases the basic strength by approximately 0.7 pK units (11). 
The reactivity of the pyrazines is somewhat similar to that of the 
other diazines and pyridine. However, they are stable to strong acid 
and strong alkali which could destroy the pyrimidine ring. The pyrazine 
ring is more resistant to alkaline permanganate than benzene. Pyrazines 
are resistant to electrophilic substitution at ring carbon atoms, so 
electrophilic attack usually takes place at the ring nitrogens. Pyra-
zines undergo a wide variety of reactions, including reduction, quater-
nization, N-oxidation, alkylation and halogenation (1). 
3 
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Pyrazines are synthesized by two general methods. These are the 
reaction of other heterocycles and the condensation of aliphatic compo-
nents. Examples of the first type are dehydrogenation of piperazines 
and permanganate oxidation of phenazines. Examples of the second type 
are reactions of alpha, beta-dicarbonyl compounds, alpha-aminocarbonyl 
compounds, alpha-halogenoketones and alpha, beta-diamines (1). 
Pyrazines occur in both foods and natural products. They are 
found in fusel oil and as products of microbial metabolism (1, 12). 
The aspergillic acids such as hydroxyaspergillic acid (I) are a group 
of antibiotic pyrazine compounds produced by cultures of Aspergillus 
(13). 2-Methoxy-3-isobutylpyrazine gives the characteristic odor to 
green bell peppers and is a major component in the steam distillate of 
the oil of those peppers (14). The presence of this compound in 
peppers indicates that biosynthetic pathways for pyrazines occur in 
higher plants as well as in molds and bacteria . 
. I 
Staudinger and R~ichstein (15) were the first to report of 
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pyrazines in foods. They found alkylpyrazines in the aroma fraction of 
c-offee. Gianturco et al. (16) indicated the probable importance of 
pyrazines in the flavor of cooked foods. In 1973 Maga and Sizer (2) 
published a review article listing pyrazines found in various food 
products. They gave an extensive list of references for the pyrazines 
found in foods. 2,3-Dimethylpyrazine was found to occur in 17 different 
food products. More recently pyrazines have been found in baked potato 
aroma and Gouda cheese (17, 18). 
Many papers have been published on the origins of pyrazines in 
roasted foods. In 1893 Stoehr produced 2,6-dimethylpyrazine by heating 
solutions of ammonia and glucose (19). In 1966 both Dawes (20) and 
Mason (21) concluded that pyrazines were formed by reactions of amino 
acids and sugars. In 1969 Wang et al. (22) proposed a mechanism for 
pyrazine formation. This mechanism involved thermal decomposition of 
sugars into dicarbonyl fragments which then reacted with amino acids. 
This adduct was then degraded to form alpha-amino carbonyl compounds 
which could condense to form pyrazines through dihydropyrazine inter-
mediates. The presence of dihydropyrazines in foods, however, has 
never been established, possibly because of the harsh treatments used 
for isolating food volatiles. Koehler (23) later showed that in the 
formation of pyrazines, carbohydrates provide the carbon atoms and 
amino acids provide the nitrogens. Further work on pyrazine formation 
in model systems was done by Koehler (24), Rizzi (3) and Wang and Odell 
(25). 
Pyrazine compounds exhibit a wide range of biological activity. 
Various pyrazines have been shown to have diuretic, anti-leprosy, 
anthelmintic, hypoglycemic, antimalarial and antibiotic activities (26, 
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27, 28, 29, 30, 13). Pyrazinamide has been used as an antituberculosis 
drug at dosages of 35 mg/kg/day (31). Some pyrazine nucleosides have 
been prepared in attempts to develop new anti-tumor agents. It was 
hoped that such unnatural nucleosides could be incorporated into nucleic 
acids and block cell division and growth (32). The pyrazirie analog of 
uracil has been shown to inhibit the growth of bacterial cells at 10-s 
molar (33). Of course pyrazines have strong organoleptic properties. 
2-Methoxy-3-isobutylpyrazine which has the odor of green peppers has an 
odor threshold of 0.002 parts per billion in water (34). 
For many years there has been interest in the use of ammoniated 
molasses as a protein substitute in cattle feed. A problem is that 
toxic by-products are formed. The convulsant 4-methylimidazole was 
suspected to be a possible toxin. In 1970 Nishie et al. (10) found 
that 4-methylimidazole was produced by ammoniation of glucose. This 
compound mimicked the toxic effects in cattle produced by ammoniated 
molasses. Mono- and dimethylpyrazines were also produced in the 
reaction. They had anticonvulsant activity. 2,3-Dimethylpyrazine had 
the strongest activity, about five per cent as strong as sodium pheno-
barbital. Since the convulsions induced in mice by 4-methylimidazole 
were prevented by alkylpyrazines, it was suggested that the ammoniation 
of feeds might be done under conditions favorable to the formation of 
such pyrazines. 
The alkylpyrazines in general have low toxicity. 2,3-Dimethyl-
pyrazine has an LD 50 in mice of approximately 1.4 mg/g as tested by 
Nishie (10). The dihydropyrazines are probably more toxic. The LD 5 o 
for 2,3-dimethyl-5,6-dihydropyrazine was shown to be 0.36 mg/g by 
Smith (35). He noted extreme muscular contractions immediately after 
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injection. 
The antituberculosis drug pyrazinamide has been shown to have many 
other biological activities. It was observed to increase pyridine co-
enzyme levels, increase prothrombin time and increase alkaline phospha-
tase (36, 37, 38). Both pyrazinam1de and pyrazine carboxylic acid have 
been found to inhibit lipolysis (39). The main side effect of pyrazin-
amide encountered clinically is urate retention. In 1957 Cullen et al. 
(40) found that the drug could cause hyperuricemia through actions on 
the tubular transport of uric acid. This has been implicated in the 
precipitation of some clinical gout (41). In fact pyrazinamide is the 
most powerful clinically encountered drug for causing urate retention, 
causing an 80-90 per cent reduction in the renal clearance of urate 
(42). In 1972 Weiner and Tinker (42) showed that pyrazinamide (II) 
exerted its uricosuric effect through its metabolite, pyrazinoic acid 
(III), which acts by inhibition of tubular secretion of urate. They 
found that the metabolism of pyrazinamide involves a slow hydrolysis 
to pyrazinoic acid followed by oxidation of pyrazinoate to 5-hydroxy-
pyrazinoic acid (IV), catalyzed by xanthine oxidase. The primary 





Since not much has been published on the metabolism of alkylpyra-
zines, studying the metabolic fate of similar compounds may be useful. 
For example in 1887 His (43) observed that pyridine was N-methylated 
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in dogs to produce an N-methylpyridinium cletabolite. N-Methylation as 
well as N-oxidation are involved in the metabolism of nicotine (44, 45). 
Nicotinamide is excreted after N-oxidation or formation of a 2- or 
4-pyridone (46). The sulfonamide drug sulfapyrazine is excreted in 
rabbits as an acetyl derivative, with the pyrazine ring remaining 
intact (47). Both histamine and imidazole-4-acetic acid are metabolized 
in mice and rats by the formation of an N-riboside. This type of con-
jugation has been implicated in the metabolism of other heterocyclic 
nitrogen compounds also (48). 
From work on 2,3-dimethylpyrazine Elgin (49) has found that 80 per 
cent of an injected dose is excreted in the urine within 24 hours. Less 
than one per cent of the dose was expired as 14C0 2 during the same 24 
hours. In earlier work Koehler (50) reported on the urinary excretion 
of unchanged dimethylpyrazine. He found that 2.5 per cent and 1.1 per 
cent of the injected dose was eliminated unchanged in the urine in 24 
hours after 75 and 50 mg doses, respectively. Forty-three hundredths 
per cent of a 70 mg dose was eliminated unchanged through the lungs. 
Smith (35) studied the urinary metabolites of 2,3-dimethyl-5,6-dihydro-
pyrazine. He found 43 per cent of an injected dose to be excreted in 
the urine in 24 hours. Three major and five minor urinary metabolites 
were separated using column chromatographic techniques. Thus, part of 
the higher toxicity of the dihydro compound may be due to its slower 
metabolism. 
Recently Hawksworth and Scheline (51) reported on the metabolism of 
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several pyrazine derivatives that are important to food flavor. They 
studied the urinary metabolites of alkyl and alkoxypyrazines in rats. 
They found that alkyl-substituted compounds were oxidized to their 
corresponding acids and excreted as acids or their glycine conjugates. 
In the case of 2,3-dimethylpyrazine which has two adjacent alkyl groups, 
alkyl oxidation was less extensive and the major metabolite found was 
2,3-dimethyl-5-hydroxypyrazine. Using an intragastric dose of 100 
mg/kg they found that aliphatic oxidation and ring hydroxylation 
accounted for 13 and 37 per cent of the dose, respectively. No glycine 
conjugates were observed. Analogous studies on pyridine compounds 
showed the same pattern of alkyl oxidation predominating except when 
two adjacent alkyl groups were present. They found that 2-methoxy-
pyrazine and 2-methoxypyridine were both metabolized by 0-demethylation 
and ring hydroxylation. No evidence was found for either N-oxidation 
or biliary excretion of any of the pyrazine derivatives. 
Whenever compounds normally considered as foreign (xenobiotics) 
gain entry to a mammalian system they are usually metabolized to other 
substances. These reactions are commonly referred to as detoxification 
reactions (48). In reality the foreign compound is either metabolized 
to a less toxic and usually more polar compound, metabolized to a more 
toxic compound, or excreted unchanged. Increasing the polarity of a 
compound increases its solubility and usually increases its rate of 
excretion. Detoxification mechanisms can involve two phases. The 
first phase involves oxidation, reduction or hydrolysis, while the sec-
ond phase is a synthetic one, usually involving a conjugation. An 
example of this is benzene which is oxidized to phenol and excreted as 
the glucuronide conjugate (48). 
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Most foreign compounds are metabolized in the liver but metabolism 
may also occur in other organs such as the kidneys, lungs, intestinal 
mucosa~ blood and skin. Most of the oxidative reactions take place in 
the endoplasmic reticulum (microsomes) of hepatocytes but the exact 
intracellular location of metabolism varies with respect to the reaction 
type and animal species involved. Glycine conjugation occurs in the 
liver mitochondria of rats but only in the kidneys of dogs. Glucuronic 
acid conjugation occurs in the liver microsomes (48). Some other 
reactions, such as alcohol oxidation occur in the soluble fraction (52). 
In all tissues capable of metabolizing xenobiotics the endoplasmic 
reticulum is the site where most of the oxidation reactions are cen-
tered. The cytochrome P-450 system is responsible for a large number 
of these reactions. This system transfers an oxygen atom frommolecular 
oxygen to the compound metabolized. The cytochrome itself is present 
in the cell in a protein-bound form and it is the nature of this 
protein that is thought to determine the specificity of these reactions. 
Xenobiotics are mainly excreted in the urine, bile and feces. 
Recent studies have shown that the mode of excretion depends on molec-
ular weight. Compounds under a certain molecular weight are excreted 
mainly in the urine, while compounds above that weight are excreted in 
the bile. This number, defined as the point at which there is at least 
ten per cent biliary excretion, varies with different species. For 
anionic compouqds, it is about 325 in rats and probably about 500 in 
man (53, 54). For monoquaternary ammonium cations, the figure is about 
200±50 (55). 
A number of factors can affect the metabolism of foreign compounds. 
Many of these are discussed in articles by Williams and Milburn (50) 
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and Vessel et al. (56). Some of the basic factors are species, age, 
strain, route of administration, time of day, sex and nutritional state. 
One of the most important affectors is the presence of another foreign 
' 
compound. Many such compounds induce or inhibit the detoxifying 
enzymes. This phenomena 'was first observed by Brown, Miller and Miller 
(57). They found that the oxidation of carcinogenic dyes was enhanced 
in animals pre-treated with the dyes. It has since been shown that 
this induced system is located in the liver microsomes. This effect, 
known as microsomal enzyme induction, appears to involve an increased 
rate of enzyme synthesis (58). The components of the P-450 system have 
also been shown to increase in amounts during induction (52). 
Since the speed in which a drug is metabolized determines the 
duration and intensity of its action, enzyme induction is very important 
pharmacologically. For example barbiturates decrease the effect of 
coumarin anticoagulants by increasing their rate of metabolism. The 
effect is also important since the natural steroid hormones are hydroxy-
lated by the same inducible system (59). The inducers vary widely in 
structure. Phenobarbital is the classic inducer, but hundreds have 
been identified. As an example a diet of charcoal-broiled meat has been 
shown to significantly alter the rate of phenacetin metabolism in man 
(60). 
CHAPTER III 
MATERIALS AND METHODS 
A. Materials 
Ethylenediamine and diethyl ether were obtained from Fisher 
Scientific Company, Chemical Manufacturing Division, Fair Lawn, New 
Jersey. 2,3-Butanedione was purchased from Eastman Kodak, Rochester, 
New York. Pfaltz and Bauer, Inc. of Flushing, New York supplied 
catalytic copper chromite. 14C-ethylenediamine was obtained from New 
England Nuclear of Boston, Mass. Alumina was from ALCOA Chemicals, 
Bauxite, Arkansas. Dowex 50WX8 and Dowex 1X8 were from J. T. Baker 
Chemical Co., Phillipsburg, New Jersey and Bio-Gel P-2 was supplied 
by Bio-Rad Laboratories, Richmond, California. Cellulosepulver MN300, 
Silica Gel G and Suprapur potassium bromide were purchased from Brink-
man Instruments, Westbury, Ne~ York. ChromAR 500 and magnesium chloride 
were from Mallinkrodt Chemical Works, St. Louis, Missouri. Aldrich 
Chemical Co. of Milwaukee, Wisconsin supplied pyrazinamide, pyrazine-2-
carboxylic acid and 2,3-pyrazine dicarboxylic aciq. 2,3-dimethylpyra-
zine was from Chemicals Procurement Laboratories, Inc. of State College, 
Pennsylvania (used only as a reference compound). Propylene glycol was 
supplied by the Oxirane Chemical Company, Houston, Texas. Injection 
sodium phenobarbital U.S.P. was from Wyeth Laboratories, Inc., Phila-
delphia, Pennsylvania. Sigma Chemical Co. of St. Louis, Missouri 
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supplied NADH, NADP, glucose-6-phosphate, glucose-6-phosphate dehydro-
genase, and nicotinamide. CD-1 strain albino male mice were from the 
Charles River Co., Wilmington, Mass. and Holtzman albino rats were from 
the Holtzman Co., Madison, Wisconsin. All animals were housed in 
plastic cages with metal lids and a bedding of crushed corn cobs. The 
animals were given Purina Rat and Mouse Pellets (Eckroat Seed Co., 
Oklahoma City, Oklahoma) and water ad libitum. 
B. Synthesis of 5,6-14C-2,3-Dimethylpyrazine 
The synthesis of both 2,3-dimethylpyrazine and 5,6-14C-2,3-di-
methylpyrazine involved the same two step reaction. The first step, 
based on the method described by Flament and Stoll (61), was the con-
densation of ethylenediamine with 2,3-butanedione. The resulting 
compound, 2,3-dimethyl-5,6-dihydropyrazine, was then catalytically 
dehydrogenated in the second step, as described by Kitchen and Hanson 
(62). The product, 2,3-dimethylpyrazine, was then distilled in vacuo 
and stored dessicated under nitrogen at -6° C. 
The first reaction step was conducted in a half-liter three-neck 
round-bottom flask. A twelve-inch water-cooled condenser was placed 
in one neck of the flask and a 125 milliliter separatory funnel was 
placed in the other neck. The center neck was fitted via ground glass 
connectors to a motor driven Teflon stirrer. The motor was powered by 
compressed air. The flask was two-thirds submerged in an ice-water 
bath. 89.7 millimoles of ethylenediamine was reacted with a twenty-five 
per cent excess of 2,3-butanedione (112.1 millimoles), each reactant 
diluted with diethyl ether to a 1:10 weight-volume ratio. Both the 
ethylenediamine and the 2,3-butanedione were purified by fractional 
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distillation before use. The same reactant amounts were used for the 
synthesis of unlabelled and 14C-labelled dimethylpyrazine. For the 
labelled compound the ethylenediamine was spiked with 250 microcuries 
of ethylene-1,2-14C-diamine dihydrochloride, having a specific activity 
of 1.82 millicuries per millimole. In the synthesis the ethylenediamine 
was placed in the cooled reaction flask and allowed to cool for a few 
minutes. The 2,3-butanedione was then added dropwise with stirring, 
taking one hour for the addition. The mixture was then stirred an 
additional fifteen minutes at 0° C, allowed to come to room temperature 
and stirred for fifteen minutes at room temperature. Using a separatory 
funnel, the ether layer was removed and the aqueous layer was extracted 
with six fifteen-milliliter washes of diethyl ether. The ether frac-
tions were then pooled and concentrated on a rotary evaporator. 
For the second reaction step the concentrated ether fraction con-
taining the dihydropyrazine was slowly added from a dropping funnel 
through a three-fourths by five-inch catalytic column of ten per cent 
copper chromite on eight to fourteen mesh F-1 alumina at 300° C. The 
bottom of the column was connected to a two-neck flask with a twelve-
inch water-cooled condenser fitted in the other neck. This flask was 
mounted in an ice-water bath. The catalytic column was heated with an 
asbestos heating tape wrap controlled by a rheostat. 
The resulting 2,3-dimethylpyrazine was purified by fractional 
distillation under reduced pressure. The round-bottom flask from the 
second reaction step was fitted with a three-inch reflux condenser 
attached to a four-inch water-cooled condenser. The condenser was 
coupled through a vacuum nipple to a water aspirator. The end of the 
condenser was connected through a ground glass joint to a collection 
15 
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flask with three 50 milliliter round-bottom flasks attached. The flask 
containing the impure dimethylpyrazine was heated with a heating mantle 
coupled to a rheostat. The solution was distilled at 12-14 millimeters 
o~ mercury absolute pressure. The second fraction, boiling at 47.5 to 
49° C was collected as the purified 2,3-"imethylpyrazine. 
C. G.is-Liqu:i.d Chromatography 
A Perkin-Elmer 990 gas-liquid chrbmatograph with a flame ionization 
detector was used. A one-fourth inch by six foot column packed with 
five per cent carbowax 20M (wt./wt.) on 100/120 mesh Gas Chrome Q was 
used. The column was operated isothermally at 130° C with nitrogen as 
the carrier gas at seven ml/min. Both the injector and detector tern-
peratures were 250° c. Two microliter samples at a concentration of 
500 micrograms per ml. in methylene chloride were injected. 
D. Liquid Scintillation Counting 
Packard Model 3320 liquid scintillation spectrometers were used 
for the majority of this study. A Beckman LS-3150T instrument was also 
used. Standard glass counting vials with ten ml. of counting cocktail 
mixed according to Bray (63) were used. Quench corrections were made 
using the channels ratio method. 
E. Toxicity Studies 
The LD 50 (lethal dose <O%) of the synthesized 2,3-dimethylpyrazine 
was determined using the classic method of Reed and Muench (64). Albino 
male mice (25-30 gram) were injected intraperitoneally with 0.25 ml. of 
different dilutions of 2,3-dimethylpyrazine in sterile 0.9% saline. 
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Four mice were used at each dilution. A one c.~. tuberculin syringe 
equipped with a 26-gauge one-half inch needle was used. The mice were 
observed for three days after injection, but all the mice that died did 
so within an hour after injection. 
F. Injection·and Urine Collection 
For the purpose of metabolite isolation, adult (at least 250 gram) 
male rats were each injected intraperitoneally with one ml. of a solu-
tion .containing 3.53 x 10 6 dpm (about 50 mg) of 5,6-14C-2,3-dimethyl-
pyrazine in 0.9 per cent sterile saline. The animals were then placed 
in a round metabolic cage fitted over a large glass funnel with a sheet 
of window screen on the top of the funnel to trap feces. The funnel 
was fitted on the bottom with an Erlenmeyer collection flask mounted in 
an ice-water bath. The animals had free access to water only. At the 
end of the 24 hour collection period, the urine was suction-filtered 
using a Buchner funnel with Whatman No. 4 paper and stored at -10° C. 
G. Column Chromatography 
Several types of columns were used for the isolation and charac-
terization of the various metabolites of dimethylpyrazine. All samples 
were concentrated by lyophilization prior to use. For preparative 
anion exchange chromatography Dowex 1X8 formate form 100-200 mesh resin 
was used. The 1.9 X 65 em. columns were operated with a head pressure 
of 110 em. and a flow rate of one ml/min. The columns were eluted with 
a gradient of increasing formate ion concentration by using a two-
chamber reservoir. A 500 ml. quantity of water was added initially to 
both the mixing and upper reservoirs. This was followed by successive 
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additions of 500 ml. each of the following eluents to the upper reser-
voir: 2N formic acid, 4N formic acid, 4N formic acid plus 0.2N 
ammonium formate and 4N formic acid plus l.ON ammonium formate. For 
analytical purposes, 0.6 X 17 em. columns of 200-400 mesh Dowex 1X8 and 
200-400 mesh Dowex 50WX8 were used with 44 em. head pressure, 0.2 ml. 
per minute flow rate and 15 ml. of each eluent. The eluents for Dowex 
50 were deionized water, lN, 2N and 3N hydrochloric acid. The eluting 
system for the Dowex 1 columns was modified for different sample types. 
Sephadex G-50 medium and Bio-Gel P-2 100-200 mesh columns were 
used for molecular sieve chromatography. The G-50 column was 1.9 X 73 
em. with a head pressure of 19 em. The P-2 column was 1.5 X 83 em. 
with a head pressure of 90 em. A smaller 1.2 X 45 em. P-2 column with 
a 30 em. head pressure was used in the in vitro studies. All molecular 
sieve columns were eluted with 0.02 molar ammonium bicarbonate. 
H. Thin Layer Chromatography 
Coated glass plates (20 X 20 em.) were prepared according to Stahl 
(65). A slurry of 15 grams Cellulosepulver MN 300, 6 grams Silica Gel 
G and 120 ml. water was mixed in a Waring blendor for 60 seconds and 
poured to a thickness of 0.75 mm. with a commerical applicator (Brink-
man Instruments Co.) (66). The plates were allowed to air dry and were 
activated for 30 minutes in an 80° C drying oven immediately before use. 
Two solvent systems were used. Solvent system number one was n-butanol, 
acetic acid, acetone, five per cent ammonium hydroxide and water in a 
7:3:5:3:2 ratio. Solvent number two was t-amyl alcohol, formic acid 
and water in a 3:2!1 ratio. For preparative chromatography samples were 
applied using a Bu:r;kard typeS. A. 20 TLC applicator (Burkard Mfg. Co., 
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Ltd., Rickmansworth, England). Using this method the sample was 
applied in a long "streak" four millimeters wide across each plate. 
After development the separate bands were located ~ith ultraviolet 
light, scraped off, eluted with deionized water on a Buchner funnel and 
lyophilized. The same procedure was then used for the second solvent 
system. 
For final purification, each metabolite fraction was streaked onto 
20 X 20 em. sheets of ChromAR No. 500 sheets, which are composed of 70% 
SilicAR-TLC 7F and 30% glass fiber. The sheets were developed with 
chloroform, methanol and concentrated ammonium hydroxide in ratios of 
30:25:1 or 100:50:3. After development each sheet was cut to a 2.5 em. 
horizontal strip centered at the Rf of the metabolite. These strips 
were then eluted via descending chromatography into glass vials until 
no ultraviolet absorbing material could be observed on the strip. The 
resulting 0.5 to 1.0 ml. of effluent was combined with 5 ml. of deion-
ized water and lyophilized. 
I. Ultraviolet Spectroscopy 
The ultraviolet spectra of metabolites number one, two, three and 
four and various pyrazine standards were obtained using a Cary Model 14 
double-beam spectrophotometer. Samples of proper concentration to 
yield maximum absorbances of about 0.8 were scanned from 340 to 220 
nanometers. The buffers used for pH 1, 7 and 11, respectively, were 
0.1 N hydrochloric acid, 0.1 M sodium phosphate buffer and 0.001 N 
sodium hydroxide. 
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J .. Mass Spectrometry 
Low resolution mass spectra were obtained using a prototype LKB-
9000 mass spectrometer (67). Samples were introduced using a direct 
probe. Spectra were obtained under the following conditions: ionizing 
voltage, 70 electron volts; trap current, 60 microamps; electron multi-
plier voltage, 1.9 or 2.1 kilovolts; source temperature, 250° C; scan 
speed, 5; paper speed, 4 in/sec artd filter, 120. 
High resolution spectra were obtained using a Consolidated Electro-
dynamics Type 21-llOB instrument (Consolidated Electrodynamics, Mon-
rovia, California), The spectra were recorded on Ilford type Q2, 2 X 15 
inch glass photographic plates, under the following conditions: ioniz-
ing voltage, 70 volts; source temperature, 270° C; trap current, 70 
microamps; accelerating voltage, 7.2 kilovolts; background pressure, 
2 X 10- 6 torr; electron multiplier, 182 volts. Individual peak masses 
were calculated by comparison to perfluorokerosene standard peaks which 
were simultaneously exposed onto the plate. 
K. Infrared Spectroscopy 
Infrared spectra were obtained using a Perkin-Elmer Model 457 
grating infrared spectrophotometer. KBr micropellets (1.5 mm. diameter) 
were made using a Perkin-Elmer micropellet press. Samples were scanned 
at medium speed and slit setting six. 
L, Magnetic Resonance Spectroscopy 
Proton magnetic resonance spectra were obtained using a Varian 
XL-100 NMR spectrometer. Samples were placed in five mm. tubes either 
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neat or in 99.87 mole per cent deuterium oxide. To lessen interference 
from contaminating H20 and HOD, some samples were lyophilH:ed, taken up 
in one ml. of D20, lyophilized and taken up again in D20. Spectra were 
obtained under the following conditions: spin rate, 30 r.p.s.; sweep 
width, 1000 Hz; sweep offset, 86025 Hz from D20 or 83701 Hz from tetra-
methylsilane; scan time, 250 seconds; filter, 2 Hz; temperature, 25° C. 
M. Metabolite Hydrolysis 
Approximately one micromole of metabolite number three was mixed 
with one milliliter of hydrochloric acid of such strength as to yield 
a final concentration of six normal. This solution was hydrolyzed in 
a sealed evacuated 18 X 150 mm. test tube for 22 hours at 110° C. It 
was then lyophilized in a vacuum dessicator over potassium hydroxide 
and stored at -10° C. A known amount of norleucine was often added as 
an internal standard. 
N. Amino Acid Analysis 
Amino acid analyses were obtained using an instrument constructed 
by Dr. Ta-Hsiu Liao of the Biochemistry Department of Oklahoma State 
University. The instrument was an adaption or the design of Spackman, 
Stein and Moore (68) using small ion exchange columns to detect amino 
acids in the nanomolar range. 
0, Separation and Esterification 
of Metabolite Fragments 
The hydrolyzed fragments of metabolite number three were separated 
into acidic and basic fractions by chromatographing the 6 N HCl 
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hydrolyzate on a 0.5 X 8.0 em. column of Dowex 50WX8 proton form 20-50 
mesh resin in a disposable pipette. The acidic fraction was eluted 
with 20 ml. of deionized water and the basic fraction was eluted with 
20 ml. 6 N HCl. The fragment fractions were lyophilized and then 
esterified using a modification of the method of Biemann et al. (69). 
Each fraction was refluxed with two ml. of 2.2 N ethanolic HCl for two 
hours, evaporated to dryness over potassium hydroxide in a vacuum 
dessicator and resuspended in two ml. of methylene chloride. Gaseous 
ammonia was bubbled through the solution for a few seconds to yield 
the free esters and precipitate the chloride as ammonium chloride. The 
solution was then filtered through a disposable pipette with a glass 
wool plug and taken to dryness in a vacuum dessicator. The ethanolic 
HCl was made by bubbling gaseous hydrogen chloride through absolute 
ethanol and calibrating the product by titration with 1.00 N sodium 
carbonate. 
P. Determination of Urinary Excretion Rates 
Two albino male 400 gram rats were each injected intraperitoneally 
with 3.55 X 10 6 dpm (approximately 50 mg) of 14C-dimethylpyrazine in 
one ml. of sterile saline. Three albino male 30-35 gram mice were 
given 1.18 X 10 5 dpm (1.7 mg.) in 0.2 ml. Urine was collected as 
described in section F at fixed intervals, except that after each 
collection period the apparatus was flushed wi~h about 30 ml. of de-
ionized water. Food and water were given ad lib. Each urine sample was 
counted in triplicate using liquid scintillation with 0.2 ml. deionized 
water and 10 ml. counting cocktail. 
22 
Q. Determination of Metabolite Percentages 
To determine the percentage of excreted radioactivity accounted for 
by each metabolite, two albino male 400 gram rats were each injected in-
traperitoneally with 3.92 X 106 dpm (approximately 50 mg.) of 14C-
dimethylpyrazine. Urine was collected daily for five days. Two ml. of 
each urine sample was chromatographed in duplicate on 0.6 X 17 em. 
Dowex 1 columns as previously described, The eluting solutions were 
15 ml. each of deionized water, 3 N formic acid, 4 N formic acid and 
4 N formic acid plus 0.2 N ammonium formate, and 40 ml. of 4 N formic 
acid plus 1.0 N ammonium formate. The four metabolite peaks of each 
run were pooled, lyophilized, dissolved in three ml. of water and 
counted with liquid scintillation. 
R. Dimethylpyrazine Metabolism in the Mouse 
Three albino male 30-35 gram mice were injected intraperitoneally 
with 5,09 X 105 dpm (7.5 mg.) of 14C-dimethylpyrazine in 0.15 ml. 
saline. The urine from the first 24 hours was filtered, lyophilized 
and dissolved in 50ml. deionized water. A rough determination of the 
metabolite percentages was made with a single Dowex 1 run as described 
in section Q. 
S. Mouse Tissue Time Course Studies 
Albino male 30-36 gram mice were each injected with 1.20 X 10 5 dpm 
(about 2 mg.) of 14C-dimethylpyrazine. At several fixed times after 
injection a mouse was sacrificed by decapitation. Blood (0.5 to 1.0 
ml) was allowed to flow into a 20 ml. beaker containing 20 U.S.P. units 
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of heparin in 20 microliters of deionized water (6 mg/ml). Within two 
minutes after sacrifice both kidneys and the liver were removed and 
placed on ice. After weighing the removed organs they were processed 
as follows. The kidneys were minced and then homogenized with ten 
passes in three minutes on a Potter-Elvehjem type Teflon in glass 
homogenizer after adding one ml. of 0.6 N perchloric acid per gram 
tissue. After setting five minutes the homogenate was centrifuged for 
10 minutes at 700 X g using a Sorvall RC-2B centrifuge with an SS-34 
rotor. All centrifugations mentioned in this thesis were done at 4° C. 
Fifty per cent perchloric acid was then added to the supernatent, 0.6 
ml. acid per ml. supernatent. After setting for five minutes the solu-
tion was centrifuged again. The collected blood was processed in the 
same manner except that only one ml. of 0.6 N acid was added. The liver 
was processed in the same manner as the kidneys except that an equal 
volume of 95 per cent ethanol was added to remove glycogen before the 
final centrifugation. The resulting supernatents were then counted 
using liquid scintillation. 
T. Rat Organ Homogenate Studies 
Male 250 gram rats were fasted for twelve hours and then sacrificed 
by decapitation. The liver, kidneys, lungs and the first 15 em. of the 
small intestine were removed, weighed and put on ice. Before weighing 
the small intestine was cleaned by gently dispensing 20 ml. of ice-cold 
0.25 M sucrose through it with a syringe. The tissues were then minced 
and homogenized in four volumes of 0.25 M sucrose (8 volumes for lung 
and small intestine). The homogenization was done with 12 passes in 
five minutes on a motor driven Potter-Elvehjem homogenizer at 425 rpm 
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(640 for lung and small intestine). Aliquots of each homogenate were 
incubated in duplicate with 14C-dimethylpyrazine. The 5.04 ml. incu-
bation mixtures were prepared by mixing 1 ml, homogenate, 3 ml. 0.1 M 
sodium phosphate buffer pH 7.4, one unit of glucose-6-phosphate dehy-
drogenase (Sigma type XV) in 20 microliters of water, 7.88 X 104 dpm of 
14C-dimethylpyrazine in 20 microliters water, and 1 ml. of a cofactor 
solution. The cofactor solution contained 5 micromoles NADP, 30 micro-
moles glucose-6-phosphate, 50 micromoles magnesium chloride and 25 
micromoles nicotinamide in one ml. of phosphate buffer. This is an 
adaption of the incubation medium used by Holcslaw et al. (70). Two 
controls were run in duplicate for each sample. For one -control, the 
homogenates were denatured for two minutes in boiling water before use. 
For the other 3500 dpm o~ purified urinary metabolite number three was 
substituted for the 14C-dimethylpyrazine. The incubations were done 
in 18 X 150 mm. test tubes on a Controlled Environment Incubator Shaker 
(New Brunswick Scientific Co,, New Brunswick, New Jersey) for 30 
minutes at 37° C and 120 oscillations per minute. The tubes were each 
sealed with a piece of Parafilm "M" laboratory wrap to retard pyrazine 
evaporation. The reaction was stopped by the addition of one ml. of 
50 per cent perchloric acid, stirred and centrifuged for 10 min. at 
1000 X g with an RC-2B centrifuge equipped with an SS-34 rotor. The 
supernatent was neutralized to pH 6.5 to 7.5 with 8 N potassium hydrox-
ide using a pH meter and then centrifuged as before. The resulting 
supernatent was lyophilized for at least 24 hours and taken up in 3 ml. 
deionized water. All samples were counted in duplicate with liquid 
scintillation using 0.5 ml. sample, 1.5 ml. water and 10 ml. counting 
cocktail. 
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U. Rat Liver Subfraction Studies 
Rats were fasted and sacrificed as described in section T. Five 
grams of liver was homogenized in 40 ml. of 0.25 M ice-cold sucrose 
with six passes in three minutes with a loose-fitting Potter-Elvehjem 
' . 
type homogenizer at 425 rpm. The homogenate was centrifuged for 10 
minutes at 750 X g (2500 rpm) with an RC-2B centrifuge equipped with 
50 ml, tubes in an SS-34 rotor. The pellet was washed with 20 ml. of 
sucrose solution and re-centrifuged. The resulting pellet was resus-
pended to 25 ml. final volume with sucrose solution to yield the nuclear 
fraction. The supernatents were then combined and centrifuged for 20 
minutes at 10,000 X g (9200 rpm on the SS-34 rotor). The pellet was 
washed with 20 ml. of sucrose solution, re-centrifuged and resuspended 
to 25 ml. to yield the mitochondrial fraction. The 10,000 X g super-
natents were then combined and centrifuged for 30 min. at 113,700 X g 
(40,000 rpm) in a Beckman LS-65 ultracentrifuge with a 60 Ti rotor and 
2.5 X 8.9 em. Polyallomer tubes. The pellet was resuspended to 25 ml. 
to yield the microsomal fraction and the supernatent was used as the 
soluble fraction. 
The incubation, processing and counting were done as described in 
section.T with the following exceptions: 2 ml. of each cellular frac-
tion was used in each incubation, 5 micromoles of NADH were added to 
the cofactors, and 2000 X g centrifugations were used to prepare the 
sample for liquid scintillation, Only boiled tissue fractions were 
done as controls. 
Another subfraction experiment was done to compare the pyrazine 
metabolizing activity of the 10,000 X g pellet and supernatent of rat 
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liver. The procedures were the same as those used for the previously 
described subfraction except for the tissue preparation. Five grams of 
liver were homogenized with 35 ml. of either 0.25 M sucrose pH 7.4 or 
0.1 M sodium-phosphate buffer pH 7.4. After five passes in two minutes ' 
with the loose-fitting Potter-Elvehjem homogenizer, the homogenate was 
centrifuged for 20 minutes at 10,000 X g (9200 rpm on the RC-2B with 
SS-34 rotor), After decanting the supernatent, the pellet was resus-
pended with sucrose or sodiUm-phosphate buffer to a volume equal to 
that of the supernatent, Protein was determined using a modification 
of the Lowry method using bovine serum albumin as the standard protein 
(71). 
V. Induction Studies 
Albino female rats (250±25 g) were injected daily with either 
sodium phenobarbital, 2,3-dimethylpyrazine or a control solution. They 
received 80 mg/kg in 0.15 ml. on day one and 60 mg/kg in 0.11 ml. on 
days three, five, six and seven, The control injection solution of 10 
per cent ethyl alcohol and 95 per cent propylene glycol was the solvent 
used for the other two solutions. Four rats were used for each solution 
type. On day eight, two animals from each group were used for liver 
homogenate experiments. The tissue preparations, incubations, pro-
cessing and counting were done as described for liver tissue in section 
T with the following exceptions: two units of glucose-6-phosphate 
dehydrogenase were used, six passes in two to three minutes were used 
for homogenization and 2000 X g centrifugations were used to prepare 
the samples for liquid scintillation. Also, the samples were lyophil-
ized and reconstituted twice before counting. 
On day nine the remaining animals were used for an in vivo in-
duction study. Each animal was injected intraperitoneally with 3.13 
X 10 6 dpm (about SO mg.) of 14C-dimethylpyrazine in sterile saline. 
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The pairs of animals preinjected with phenobarbital, pyrazine and con-
trol solutions were housed separately and were given only water during 
the twenty-one hour urine collection period. The urine was filtered on 
a Buchner funnel with Whatman No. 4 paper, lyophilized and dissolved in 
SO ml. of deionized water. The reconstituted urine was then analyzed 
using liquid scintillation with duplicate samples of O.S ml. urine, 
l.S ml. water and 10 ml. counting cocktail. The reconstituted urine 
samples were also used to determine the per cent of the excreted radio-
activity accounted for by each metabolite. Duplicate 0.6 X 17 em. 
Dowex 1X8 column runs were done with each of the three urine samples 
and the resulting peaks were assayed for 14C, all as described in 
section Q. 
CHAPTER IV 
RESULTS AND DISCUSSION 
A. Synthesis of 14C-Dimethylpyrazine 
The synthesis of 5,6- 14C-2,3-dimethylpyrazine (IV) was accomplished 
by the condensation of 14C-ethylenediamine (I) with 2,3-butanedione 
(II) followed by the dehydrogenation of the resulting compound, 2,3-
dimethyl-5,6-dihydropyrazine (III). The catalytic dehydrogenation 
method used was found to be quite satisfactory. One pass through the 
catalytic column yielded a convers-ion so complete that no trace of the 
dihydropyrazine could be detected by either gas-liquid chromatography 
(GLC) or nuclear magnetic resonance (NMR). The overall procedure for 
synthesis yielded a product of very high purity, as shown by the GLC 
chromatogram in Figure 1. In other GLC runs, the product was found to 
give only one peak when co-chromatographed with a sample of commercially 
produced 2,3-dimethylpyrazine. 
+ ~ (1) 





















Figure 1. Gas-Liquid Chromatogram of Synthesized 2,3-Dimethyl-
pyrazine in Methylene Chloride (see p. 15) 
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When the product was co-chromatographed with a sample of synthesized 
5,6-dihydro-2,3-dimethylpyrazine two peaks were observed. The retention 
times of dimethyldihydropyrazirte and dimethylpyrazirie were 4.8 and 4.2 
minutes, respectively. The product of fractional distillation was 
collected over a narrow temperature range since the objective was high 
purity instead of high yield. Approximately 3.5 ml. was obtained, con-
stituting about a 36% yield. The product was almost colorless. 
As a further proof of identity and purity the product was analyzed 
with NMR and mass spectrometry. As shown in Figure 2, the product 
yielded two peaks in the proper ratio of 1:3 with only a small water 
peak at 4.11 ppm. The peaks at 2.42 and 8.22 ppm are attributable to 
the methyl and aromatic protons of dimethylpyrazine, respectively. 
Smith (35) reported peaks at 2.05 and 3.19 ppm in the spectrum of 2,3~ 
dimethyl-5,6-dihydropyrazine. 
The mass spectrum of 14C-dimethylpyrazine is shown in Figure 3. 
The peak at 108 m/e represents the molecular ion. No peak was observed 
at 110 m/e, which would be the molecular ion of dimethyldihydropyrazine. 
B. Toxicity Studies 
The toxicity of some alkylpyrazines, including 2,3-dimethylpyra-
zine have been reported. However it was decided that a study was 
needed for the exact conditions of injection to be used in this work. 
Differences in impurities in the injection mixture, animal strain, 
weight and age could have profound effects. 
Using synthesized dimethylpyrazine the LD5o was determined to be 
0.7 mg/g body weight when injected intraperitoneally into albino male 
30-35 gram mice (Table I, Figure 4). The method of interpreting the 
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data was that of Reed and Meunch (64). Deaths usually occurred within 
15 minutes. The LD 50 of 2,3-dimethylpyrazine for 18-25 gram mice was 
reported to be 1.39 mg/g by Nishie et al. (10). Smith (35) has deter-
mined the LD 50 of 2,3-dimethyl-5,6-dihydropyrazine to be 0.36 mg/g. 
He reported extreme muscular contractions immediately after injection. 
No such contractions were observed in this study. 
TABLE I 
LD 50 OF 2,3-DIMETHYLPYRAZINE FOR MICE* 
Dose (mg/g) II Alive II Dead Total Alive Total Dead % Mortality 
0.2 4 0 12 0 0 
0.4 4 0 8 0 0 
0.6 3 1 4 1 20 
0.8 1 3 1 4 80 
1.0 0 4 0 8 100 
1.2 0 4 0 12 100 
1.4 0 4 0 16 100 
1.6 0 4 0 20 100 
* The LD5o value was determined to be 0.7 mg/g body weight using the 
graphical method of Reed and Meunch (64) (see p. 15). 
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C. Metabolite fsolation 
Initial studies of the urinary metabolites of 2,3-dimethylpyrazine 
revealed four reproducible metabolite fractions. Several chromate-
graphic techniques were used to purify these fractions and to determine 
I 
how many actual metabolites were present in each fraction. Through 
such studies an isolation scheme was developed to produce purified 
metabolites in quantities large enough for characterization. The urine 
from three separate experiments of three rats each was used for the 
bulk of the metabolite characterization work. 
The animals were each injected with 50 mg of 5,6-14C-2,3-dimethyl-
pyrazine. The urine collected in the first twenty-four hours after 
injection was filtered, lyophilized and dissolved in about 20 ml. water. 
The entire reconstituted sample from three rats was then chromatographed 
on a 1.9 X 65 em. column of Dowex 1X8 formate form resin. The column 
was sufficient to separate all four metabolites. Figure 5 shows the 
metabolite profile. The radioactive peaks obtained were designated one, 
two, three and four in order of their elution. Peaks two, three and 
four were anionic while peak one eluted with the water wash. Some of 
the preliminary studies with urinary metabolites on Dowex 1X8 used 
2,3-14C-2,3-dimethylpyrazine. The same four 14C peaks were observed 
using either 2,3- or 5,6-labelled compound. Thus, it is likely that 
ring scission has not taken place. 
For a control urine run five ml. of urine from an uninjected rat 
was chromatographed on Dowex 1. To determine where unchanged dimethyl-
pyrazine would elute 50 mg of 14C-dimethylpyrazine was chromatographed 
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The control pyrazine run suggested that none of the four metabolite 
peaks were due to unchanged pyrazine since each metabolite peak eluted 
in positions different from that of dimethylpyrazine. The fact that 
14C-dimethylpyrazine was lost when lyophilized provided further support. 
Because of its low boiling point (156° C) only a trace of radioactivity 
was recovered when a known amount of 14C-dimethylpyrazine was lyophi-
lized. 
Each radioactive peak from Dowex 1 was pooled, lyophilized and 
dissolved in 3-5 ml. 0.02 M ammonium bicarbonate. Each fraction was 
then passed through a gel filtration column. Previous studies had 
shown that the radioactive component of peak one was well centered in 
the elution profile of Bio-Gel P-2, while Sephadex G-50 worked well for 
peaks two, three and four. A typical chromatographic profile of peak 
one on P-2 is shown in Figure 6. The radioactive peak is separated 
from a number of other compounds. Figure 7 shows the elution profile 
of metabolite three on Sephadex G-50. Metabolites two and four elute 
at the same position. Although the radioactive peaks aren't separated 
from many ultraviolet-absorbing impurities, the gel filtration step is 
useful for removing the salts acquired from anion exchange chromato-
graphy. There also may be some non-UV-absorbing compounds separated 
by this method. 
The reconstituted lyophilized peaks from gel filtration were each 
chromatographed twice using two different solvent systems. The devel-
oped chromatograms were observed uhder short wave ultraviolet light to 
observe the bands. Small circular samples of 5 mm. diameter were 
scraped from the plate at one em. intervals from the origin to the 
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checked for radioactivity with liquid scintillation. A typical profile 
is shown in Figure 8. Figure 9 shows a conventional chromatogram of 
all four metabolites using the butanol based system. Many impurities 
are shown to be separated using this technique. The pentanol based sol-
vent system removed some additional impurities. 
After chromatographing each peak with both solvent systems the 
peaks were each re-chromatographed on gel filtration columns as before. 
This was found to be necessary since a large amount of silica gel 
dissolved in the water wash used to elute the metabolites from the 
thin-layer material. 
The final step in the purification scheme was chromatography on 
ChromAR sheets which have sorbent properties similar to the TLC silicas. 
This medium was chosen for the final purification step because less 
polar solvents could be used which would dissolve much less silica. 
Also, these sheets could be cut into strips after development and eluted 
directly via descending chromatography. A control proved the effec-
tiveness of this step for eliminating silica residue. Blank thin-layer 
plates passed through the isolation procedure yielded a small amount of 
silica residue after the gel filtration step but no detectible residue 
after the ChromAR step. Only metabolites two, three and four were 
isolated using ChrpmAR sheets. Metabolite one was only available in 
such small amounts at this point in the isolation scheme that a satis-
factory solvent system was not found for separating it on ChromAR. 
Solvent systems were developed for metabolites two, three and four which 
had Rf values of 0.45-0.55. The solvent system for metabolite two 
consisted of chloroform, methanol an? concentrated ammonium hydroxide 
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Figure 9. Thin-Layer Chromatogram of Urinary Metabolite Fractions 
from Gel Filtration Step (see p. 40) 






100:50:3. After chromatography on ChromAR the samples were lyophilized 
and dissolved in four ·ml. of deionized water. 
The complete isolation scheme is shown in Figure 10. Table II 
shows the efficiencies of the isolation scheme at various steps. The 
data presertted is the average of three experiments of three rats each. 
The quan~itative yield of 14C on lyophilization again suggests that 
none of the Dowex peaks are due to unchanged pyrazine. The yields of 
the ChromAR steps in the procedure were not monitored closely but were 
only about 50%. Since the object of the ChromAR step was high purity 
and not high yield, only the center portion of each ChromAR band was 
eluted. 
TABLE II 
EFFICIENCY AT EACH STEP OF THE METABOLITE ISOLATION SCHEME (%) 
Step 
Efficiencies of Each Step 
M 1* M 2 M 3 M 4 
Urine Lyophilization** 
Dowex 1X8*** 
Gel Filtration 84.3 92.9 89.5 77.4 
Thin-Layer 111 45.6 68.5 74.7 58.0 
Thin-Layer 112 63.2 81.4 71.3 61.8 
Gel Filtration 88.8 92.0 83.4 
*M 1, etc. indicates metabolites one, two, three and four. 
' **This step was quantitative. 
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From the isolation work it was determined that there were at least 
four major urinary metabolites of 2,3-dimethylpyrazine. Three of these 
metabolites were found to be anionic and all four absorbed light at 
280 nanometers. None of the metabolite fractions observed on Dowex 1 
chromatography were due to the excretion of unchang.ed dimethylpyrazine 
in the urine. 
To show that the metabolites isolated were true metabolites and 
not artifacts produced by pyrazine combining with urine components a 
control experiment was cbnducted. Twenty-five milligrams (1.77 X 10 6 
dpm) of 14C-labelled dimethylpyrazine was incubated with ten ml. of 
normal rat urine at 4° C for 24 hours, at room temperature for two 
hours, and then at -10° C for 24 h6urs. These conditions simulated the 
normal handling of urine used in this metabolic study. The urine was 
then chromatographed on a column of Dowex 1X8 resin, using the same 
conditions used for metabolite isolation. As shown in Figure 11 only 
one radioactive peak was obtained. The peak was observed where di-
methylpyrazine normally elutes, which was later than where metabolite 
number one eluted. Since none of the four normal metabolite peaks 
were obtained it is likely that these four compounds are all actual 
.urinary metabolites. The radioactive peak was then pooled, lyophilized, 
dissolved in four ml. of water and counted by liquid scintillation. 
The residual radioactivity accounted for 3.8% of the incubated dose. 
! : 
Much of the residual radioactivity was probably due to the occlusion of 
some dimethylpyrazine in the st~cky urine residue. 
D. Metabolite Characterization 
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purified metabolite fractions two, three and four were each lyophilized 
and analyzed with mass spectrometry and infrared and nuclear magnetic 
resonance spectroscopy. Ultraviolet spectra were obtained after dis-
solving each metabolite in four ml. deionized water. 
D.l. Ultraviolet Spectroscopy 
The various metabolites of 2,3-dimethylpyrazine are easily moni-
tored during preparatory procedures due to their strong absorbance of 
ultraviolet light at 265-280 nm. Comparing the ultraviolet spectrum of 
2,3-dimethylpyrazine (Figure 12) with those of metabolites two, three 
and four (Figures 13, 14, and 15), the spectra show the same general 
pattern. It is probable that during metabolism the pyrazine ring 
remains intact and aromatic. The absorption maxima differ by no more 
than four nanometers. Although it is an impure preparation metabolite 
fraction one also shows this same profile, with an absorption maximum 
of 276 nm. (Figure 16). Since one possible route of metabolism could 
be oxidation of the methyl group, the spectra of 2-pyrazinoic acid was 
also examined (Figure 17). Metabolites two and three both show large 
spectral shifts at pH 1 while pyrazinoic acid and metabolite four do 
not. 
D.2. Mass Spectrometry 
Metabolite number four (M4) was found to be very polar. Since it 
was the last metabolite to elute from Dowex 1 it seemed likely that it 
contained a strongly polar group such as a carboxyl. The mass spectrum 
of M4 is shown in Figure 18. The molecular ion appears at m/e 138. 
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Figure 12. Ultraviolet Spectrum. of 2,3-Dimethylpyrazine in 0.02N 
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Figure 18. Mass Spectrum of Metabolite Four (see p. 19) 
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molecule during its metabolism. Two other prominent peaks are found at 
m/e 120 (M-18) and 92 (M-46). The fragmentation pathway proceeds from 
138 to 120 to 92 as evidenced by metastable peaks at m/e 104.4 and 70.5. 
The calculated values for these metastable transitions are 104.35 and 
70.53. The loss of 18 mass units suggests the loss of water. Water 
could be eliminated from 3-methylpyrazine-2-carboxylic acid via a 
McLafferty rearrangement. The (M-46) peak is then explained by the 
further loss of C=O. This type of rearrangement was first observed by 
McLafferty and Gohlke in studies on ortho-methylbenzoic acid (72). The 
mass spectrum of M4 was then compared to that of pyrazine-2-carboxylic 
acid (Figure 19). One would expect similar fragmentation with peaks 
differing by fourteen mass units since M4 is fourteen mass units 
heavier. This was found to be the case as shown in Table III. 
TABLE III 








*Denotes strongest peaks in spectra 
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Figure 19. Mass Spectrum of 2-Pyrazinoic Acid (see p. 19) 
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These compounds show further similarity in that they both volatilize at 
25-30° C in the mass spectrometer. The probable fragmentation pathway 
of M4 is shown in equation two. 
-r!" I + . 0 
II 
();(;H r:cC=O -co + ~ H20 + -----+ [CsHtoN2] (2) 
N CH~ N CH2 
m/e 138 m/e 120 m/e 92 
The mass spectrum of metabolite number two (M2) is shown in Figure 
20. The apparent molecular ion is at m/e 153 with other prominent 
peaks at m/e 124, 108, 95, 80 and 67. The compound volatilized at 
110° C differing markedly from metabolite number four. This indicates 
the possibility of a very polar compound such as an N-oxide or salt. 
A metastable peak was observed at 90.6. High resolution mass spectra-
metry showed the exact mass of the apparent molecular ion to be 153.066. 
This compares favorably with the theoretical value of 153.067 for the 
empirical formula C7H 9 N20 2• Several other fragment peaks match well 
with logical fragment ions of the C7H9 N20 2 parent. These results are 
shown in Table IV. These major peaks are consistent with the losses of 
OH, CHO, COOH and C2H4 0 2• Other fragments differ only in the number of 
hydrogens. One possibe stru~ture fpr metabolite two would be 3-methyl-
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Figure 20. Mass Spectrum of Metabolite Two (see p. 19) 
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loss of OH to yield m/e 136 or by loss of the whole carboxyl group to 
yield m/e 108. The loss of the carboxyl group and methyl group would 
then yield m/e 93. The structure of metabolite two must account for 
pyrazine molecule. Another possible route for metabolism would be 
N-formylation and either ring or side chain hydroxylation. This could 
also yield the proper molecular weight. A possible structure would be 
1-(N-formyl)-2-hydroxymethyl-3-methylpyrazine (VI). 
v VI 
Several mass spectral peaks of M2 are also found in the mass 
spectrum of 2,3-dimethylpyrazine. These are m/e 67, 52, 42 and 40. 
Bondarovich et al. (16) has determined the empirical formulae of some 
fragments of alkylpyrazines using high resolution mass spectrometry. 
For 2,3-dimethylpyrazine they found m/e 42 to be C2 H4N and m/e 67 to 
be C4H5N. They also found that the peak at m/e 108 was C6 H8 N2 in 
eight different alkylpyrazines, including 2,3-dimethylpyrazine. The 
empirical formula for the m/e peak in M2 was also found to be C6 H8 N 
(Table IV). This is additional evidence that the pyrazine ring 
structure has not been destroyed by metabolism to ,metabolite number 
two. 
TABLE IV 
HIGH RESOLUTION MASS SPECTROMETRY RESULTS FOR METABOLITE TWO 
60 
m/e Observed Mass Calculated Mass Empirical Formula 
153~'<' 153.067 153,066 C7H9N202 
136* 136,060 136.064 C7HeN20 
137 137' 073 137.072 C7H9N20 
124* 124,062 124.064 C6HeN20 
122 122.046 122.048 C6H6N20 
123 123,053 123.056 C5H7N20 
125 125.067 125.072 C6H9N20 
108* 108.070 108.069 C6HeN2 
105 105.044 105.045 C5H5N2 
106 106.055 106.053 C6H6N2 
107 107.059 107.061 C5H7N2 
109 109.075 109.078 C5H9N2 
93* 93.046 93,045 C5H5N2 
94 94.052 94.053 C5H5N2 
95 95.060 95.061 C5H7N2 
*Major peaks 
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The mass spectrum of metabolite number .three (M3) is shown in 
Figure 21. The compound volatilized at 90° C in the mass spectrometer. 
The base peak is again m/e 108. Metabolites two, three and four all 
show fragments at m/e 42, 52 and 67. M2 and M3 more closely resemble 
each other. They share peaks at 153, 108, 107, 80, 67, 53, 52, 43, 42 
and 39. The peak of M3 at m/e 269 was the highest peak observed in the 
spectrum. Although the peak was of low intensity it appeared in every 
preparation of this metabolite. If the m/e 269 peak is the molecular 
ion a conjugated metabolite is likely. Simple oxidation could not 
account for the net addition of 161 mass units. Due to their similar 
Dowex 1X8 elution positions and mass spectral patterns M3 might be a 
conjugated form of M2. Some further studies on the possible cdnjugate 
structure of M3 are discussed in section D.6. 
D.3. Infrared Spectroscopy 
The infrared spectra of metabolites two and three are quite simi-
lar (Figures 22, 23). Both show strong absorption bands at 1600 and 
1400 cm- 1 and weak bands at 1960, 1300 and 1170 cm- 1 • The bands at 
1600 and 1400 cm- 1 were also observed for M4. None of the three meta-
bolites yielded any evidence for an N-oxide group ·which would give a 
very intense band at 1350-1250 cm- 1 (73). 
D.4. Nuclear Magnetic Resonance Spectroscopy 
The prqton magnetic spectra of metabolites two and three both show 
the presence of aromatic ring protons (Figures 24, 25). The values 
8.44 and 8.28 ppm both compare favorably with the value of 8.21 observed 
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would be much farther upfield. Smith '(35) has reported a value of 3.19 
ppm for the ring hydrogens of 2,3-dimethyl-5,6-dihydropyrazine. Table 
V gives a summary of the NMR data obtained for the metabolites and 
standards used. All the samples were analyzed in D20 because of solu-
bility problems encountered with less polar solvents. Thus all 
exchangable protons such as those of hydroxyl and carboxyl groups were 
not observed. 
The NMR spectrum of M2 shows peaks at 8.44, 5.04, 3.55 and 2.62 
ppm. Integration of the peaks yielded the ratios 2:2-3:6:3. The 
singlets at 8.44 and 2.62 are consistent with two aromatic ring hydro-
gens and three ring-methyl hydrogens. This indicates that dimethyl-
pyrazine has been metabolized at one methyl group and possibly also 
at the ring nitrogens. The groups responsible for the other two peaks 
have not been identified. Low humps like the one at 3.55 ppm often 
indicate hydrogen bonded to nitrogen (74). 
The data obtained for metabolite three also indicates that two 
ring-hydrogens and one ring-methyl group have remained intact. This is 
shown by the peaks at 8.28 and 2.54 in the ratio of two to three. The 
peak at 1.97 is consistent with three highly shielded protons. This 
peak and some of the others might be explained by a conjugated moiety. 
A side chain methyl could be oxidized to an alcohol or acid and thert 
conjugated with a small molecule. Conjugation might also occur at the 
ring nitrogen. 
A good NMR spectrum was not obtained for metabolite four since this 
metabolite was not produced in large quantities. Figure 26 shows the 
result of 200 time-averaged scans at a scan speed of 250 seconds per 
scan. Only one peak was observed other than the D20 peak. This peak, 
9 8 7 6 5 4 3 2 
PPM (8) 





located at 2.79 ppm, probably represents the protons of the ring-methyl 
group. 
TABLE V 
NMR PEAKS OF VARIOUS PYRAZINE COMPOUNDS 
Compound 
a) HX~N~COOH 
a) H N COOH 
Peak Values (ppm) 
a. 8.81 b. 9.17 
a. 8.82 
a. 8.83 b, 9.27 
a) H\xrN~I H3 (b 
..... , ,)(,.... a. 8.21 b. 2.49 





Metabolite Two a. 8.44 b. 5.04 c. 3.55 d. 2.62 2:2-3:6:3 
Metabolite Three a. 8.28 b. 4.28 c. 3.90 2:1-2:2:2:3:3 
d. 2. 95 e. 2. 54 f. 1. 97 
Metabolite Four a, 2. 79 
70 
D.S. Further Chromatography of Metabolite Four 
The mass spectral pattern of metabolite four (M4) strongly indi-
cated that its structure was 3-methylpyrazine-2-carboxylic acid. To 
gain further evidence metabolite four and three pyrazine standards 
were chromatographed using thin layer and anion exchange chromatographic 
techniques. Approximately 0.8 micromoles each of pyrazinamide, pyra-
zinoic acid and pyrazine-2,3-dicarboxylic acid were chromatographed 
using 0.6 X 17 em. columns of Dowex 1X8 resin. The eluents were 15 ml. 
each of H20, 3N, and 4N formic acid and 30 ml of 4N formic acid plus 
l.ON ammonium formate. Figure 27 shows the profile of the three 
standards. In a separate colUmn run, metabolite four eluted at tube 
number 47, the same elution position as pyrazinoic acid. The experiment 
was repeated using Dowex 50WX8 columns of the same size. Both M4 and 
pyrazinoic acid were eluted in the first six milliliters of the water 
wash. 
Metabolite four and the three standards were chromatographed on 
ChromAR sheets using the normal solvent system used for M4 isolation. 
The results shown in Table VI indicate that metabolite four, with an Rf 
value of 0.43, is slightly less polar than pyrazinoic acid (Rf=0.37). 
This is to be expected since the methyl group of M4 would be electron 
donating and decrease the strength of the acid. 
D.6. Further Studies on Metabolite Three 
The largest ion fragment observed in the mass spectrum of metabo-
lite three was m/e 269. This is 161 mass units higher than the 
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be a conjugated pyrazine derivative. 
TABLE VI 











*ChromAR sheets developed in chloroform:methanol:NH40H (100:50:3) 
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Forty-five hundredths micromoles of M3 was hydrolyzed in 6N 
hydrochloric acid. The resulting hydrolysate was then analyzed for 
amino acids using the method of Spackman, Stein and Moore (68). Fif-
teen hundredths micromoles of dl-norleucine was included as an internal 
standard. The sample yielded only one peak. It eluted exactly at the 
first buffer change which was after valine and before methionine. The 
peak thus did not correspond to any of the common amino acids. When an 
unhydrolyzed sample of M3 was analyzed a very, small peak was observed 
in the same position as in the hydrolyzed sample. Since the metabolite 
peak eluted exactly at a buffer change further amino acid analyses used 
only the first buffer for elution. Cystathionine was considered to be 
73 
a likely candidate for the unknown since it also eluted at the buffer 
change. However, when only one buffer was used the elution times were 
118 min. for valine, 137 for the M3 fragment and 172 and 181 for the 
two peaks from cystathionine. Thus it seemed likely that the conjugated 
moiety was an alpha amino acid with properties similar to valine and 
methionine. S-methylcysteine and norvaline are similar to methionine 
and valine, but they eluted differently from the M3 fragment. S-
methylcysteine eluted earlier than both valine and the M3 fragment, 
while norvaline eluted after the fragment. 
To check the stoichiometry of the conjugation 0.4 micromoles each 
of hydrolyzed M3 and norleucine were analyzed. Assuming the same nin-
hydrin color factor for both the M3 fragment and norleucine the ratio 
found after analysis was 1.18:1.00 (M3 to norleucine). It seems likely 
that if M3 is a conjugated metabolite the conjugation takes place with 
a stoichiometry of' one to one. 
To separate the pyrazine and amino acid-like moieties from the M3 
hydrolysate one micromole of hydrolysate was fractionated using a 0.5 
X 8 em. column of Dowex SOWX8 as previously described. The fractions 
eluting in the water and HCl washes were referred to as the H20 and HCl 
fractions. To test the system 0.25 mg. of cystathionine (about one 
micromole) and 0.25 mg of pyrazinoic acid were chromatographed. All of 
the pyrazinoic acid and cystathionine was eluted inthe H20 and HCl 
fractions, respectively, as monitored by ultraviolet absorbance and 
ninhydrin. Using hydrolyzed M3 the amino acid-like moiety was found 
only in the HCl fraction as monitored by amino acid analysis. This 
compound eluted from the analyzer at the same position in both frac-
tionated and unfractionated samples. 
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The HCl fraction was lyophilized and analyzed using mass spectro-
metry. The results were very ambiguous. Amino acids often give 
unacceptable spectra due to decomposition and formation of diketopiper-
azine dimers (75). Ethyl esters of amino acids can be made with ethan-
olic-HCl as described by Biemann et al. (69) ,. They found prominent 
peaks at (M-73) and (M-102) which were caused by cleavage at either 
side. of the alpha carbon. Using the method described ih chapter three 
ethyl esters of alpha-aminobutyric acid and the HCl fraction of M3 were 
prepared. The spectrum of ethyl alpha-aminobutyrate correlated well 
with the expected fragments. However the spectrum of the ethylated M3 
fragment was poor. The major peaks were at m/e 42, 108, and 139. 
Better spectra might be obtained by using the amino acid analyzer to 
purify to HCl fraction and by using minimal amounts of solvents for 
derivatization. 
The amino acid analysis of hydrolyzed M3 also indicated a small 
amount of cysteine. A cysteine conjugate could be expected to be 
altered by performic acid oxidation, About 20 nanomoles of hydrolyzed 
M3 were oxidized with performic acid. One volume of 30% hydrogen 
peroxide was mixed with nine volumes of 98% formic acid and allowed to 
stand at room temperature for one hour. The oxidation was conducted 
at 0° C for one hour using 0.1 ml of the acid solution. Amino acid 
analysis of the product yielded a peak eluting at 43.6 minutes, compared 
to 146.9 minutes for the unoxidized sample. A small cysteic acid peak 
was also observed. This change in elution time closely parallels the 
shift observed for the oxidation of methionine to methionine sulfone. 
From these results a possible structure for M3 is 2,3-dimethylpyrazine-
5-mercapturic acid (VII). 
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This structure is consistent with the release of a ninhydrin-
positive group upon hydrolysis, the release of small amounts of cysteine 
and cysteic acid and the change in elution time upon oxidation. The 
mass spectral peaks of M3 also support this structure (Figure, 21). The 
molecular ion at m/e 269 yields the appropriate molecular weight. 
Cleavage at either side of the sulfur atom would yield fragments at 
m/e 107, 130, 140, and 162. Loss of COOH would yield m/e 224 and the 
m/e 43 peak could be due to the acetyl group. 
VII 
E. Elimination Rates of Dimethylpyrazine 
Work on the isolation of the urinary metabolites of 2,3-dimethyl-
pyrazine utilized the urine excreted in the first 24 hours after 
injection. It was observed that approximately seventy to eighty per 
cent of the injected 14C was excreted in the urine during that time 
period. Further studies were performed to determine more exact excre-
tion rates. 
Table VII shows the amounts of radioactivity excreted during each 
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twelve hour period after injecting two rats with 50 mg. of 14C-2,3-
dimethylpyrazine. Most of the radioactivity is excreted during the 
first twelve hours and very little is excreted after forty-eight hours. 
These results are in agreement with earlier work done by Elgin (49) 
with 2,3-14C-labelled dimethylpyrazine. He found that less than one 
per cent of the dose was excreted after the first two days. 
TABLE VII 
EXCRETION OF 14C IN THE URINE OF RATS INJECTED 
WITH 5,6-14C-2,3-DIMETHYLPYRAZINE* 






96 Hour Total 81.2 
*Two rats were administered doses of 3.55 X 10 6 dpm. 
The excretion rate of dimethylpyrazine in mice was also checked. 
Three mice were each injected with 1.7 mg. of 14C-dimethylpyrazine. 
Nine-tenths per cent of the 14C was excreted in the first ten hours and 
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49.2 per cent was excreted in the second ten hours. Very little was 
excreted after twenty hours. A total of 52.4% was excreted in 132 
hours. Smith (35) has reported on the urinary excretion of 2,3-di-
methyl-5,6-dihydropyrazine in mice. He reported 43% excreted in the 
first 24 hours and 55% during the first five days. Thus the dihydro 
compound £s excreted at a rate that is similar to that of its aromatic 
analog. The renal clearance rates of dimethylpyrazine in rats and mice 
are similar to rates for pyrazinamide in dogs. Weiner and Tinker (42) 
found that after intravenous administration of one gram of pyrazinamide 
in dogs 30% was excreted in six hours and 70% was excreted in 24 hours. 
The results of Dowex 1X8 chromatography showed that the four 
metabolites of dimethylpyrazine differed greatly in charge. Since the 
urinary excretion of compounds depends greatly on their charge, an 
experiment was done to see if the individual metabolites were excreted 
at different rates. Two rats were each injected with 50 mg. of 14C-
dimethylpyrazine. Their daily urine collections were chromatographed 
in duplicate on Dowex 1. The metabolite peaks were pooled and analyzed 
for 14C. Table VIII shows the results of this work. These results 
show that the percentage appearing as metabolite one sharply increases 
after the first 24 hours. The more anionic metabolites are excreted 
much faster. The excretion of metabolite four showed the sharpest 
decline. Almost all of it was excreted in the first 24 hours. These 
results are not too surprising since highly polar compounds are more 
water soluble and often excreted faster than less polar ones. 
To determine if mice metabolize dimethylpyrazine to the same 
metabolites as rats, mouse urine was analyzed using Dowex 1 columns, 
as done for rat urine. Three mice were each injected with 7.5 mg. of 
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14C-dimethylpyrazine. Using the urine from the first 24 hours only 
four radioactive peaks were observed on Dowex 1. These peaks eluted 
at the same positions in mouse and rat urine. The metabolite percent-
ages were as follows: 4% as Ml, 38% as M2, 49% as M3 and 8% as M4. 
TABLE VIII 
PER CENT OF DAILY EXCRETED 14C IN EACH METABOLITE* 
Day % 14C excreted % as Ml t % as M2 % as M3 % as M4 
1 77 .o 5.2 65.6 19.2 10.0 
2 2.7 47.6 36.0 15.2 1.3 
3 0.5 60.5 24.7 13.4 1.4 
tMl, etc. refer to Metabolites 1, etc. 
*Two rats were each injected with 50 mg dimethylpyrazine and the urine 
from each rat was chromatographed in duplicate. 
From the urinary excretion studies with rats and mice it was 
determined that a large portion of an injected dose of 14C-dimethyl-
pyrazine was metabolized and excreted during the first 24 hours after 
injection. In rats most of the 14C was excreted in the first twelve 
hours. Collection periods of less than 10-12 hours are not suitable 
because of the irregularity of urination. To more accurately determine 
the rate of metabolism a tissue time course study was done. In this 
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experiment mice were injected intraperitoneally with 2 mg. of 14C-
dimethylpyrazine. At fixed times after injection animals were sacri-
ficed and their blood, kidneys and liver were assayed for 14C. The 
results, shown in Figure 28, indicate that radioactivity is cleared 
from all three tissues very rapidly. All data points were calculated 
in terms of dpm per organ. The calculation of total blood volume was 
based on 78 ml. blood per kilogram body weight (76). The 14C levels 
reached their peaks in both liver and blood within 20 minutes and 
possibly before five minutes. A clearing of 14C from the boood by the 
kidney was readily apparent. The time course for the kidney exhibits 
a slow rise and fall, peaking at about 40 minutes. It is not possible 
to conclude whether the compound is metabolized in the liver or kidney 
since the liver contains a large amount of blood. Drabkina and Ginz-
burg (77) studied the clearance of pyrazinamide in mice. Using oral 
doses of five mg. pyrazinamide they found that maximum concentrations 
occurred in the blood, lungs, kidneys and liver at one to two hours 
after administration, with the levels decreasing rapidly in five hours. 
F. In Vitro Studies 
Metabolic studies using intact animals provide useful information 
on the disposition and final metabolites of foreign compounds. However 
such studies provide little information on the nature and sites of 
intermediate biotransformation of such compounds since only "terminal" 
metabolites are collected (78). 
Several in vitro experiments were employed in this study of di-
methylpyrazine to determine the nature and location of the metabolizing 
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pyrazine is volatile (boiling point = 156° C) while its metabolites 
are nonvolatile. The metabolites were shown to be nonvolatile by their 
quantitative recovery when metabolite-containing urine was lyophilized. 
In the in vitro experiments 14C-dimethylpyrazine was incubated at 37° C 
in a buffered mixture containing a tissue homogenate and several 
cofactors. The mixture included a NADPH-generating system of NADP, 
glucose-6-phosphate, glucose-6-phosphate dehydrogenase, magnesium 
chloride and nicotinamide in 0.1 MpH 7.4 sodium phosphate buffer. The 
nicotinamide was included to protect nucleotides from breakdown by 
nucleotidase (79). After a thirty minute incubation at 37° C the 
mixture was 'processed and lyophilized. The 14C remaining after lyophil-
ization was used to calculate the amount of dimethylpyrazine metabo-
lized. Control incubation mixtures using boiled homogenates were used 
as blanks. Another control mixture had a known amount of purified 
metabolite three but no dimethylpyrazine. This control was used to 
determine the efficiency of metabolite recovery from the incubation 
mixtures. 
The first in vitro experiments were done to determine which 
tissues metabolize dimethylpyrazine. Isotonic sucrose homogenates 
were made from the liver, kidneys, lungs and small intestine of 250 
gram male rats. Table IX shows the relative metabolizing activities 
of the four tissues. The values were obtained from duplicate homage-
nates from each of three rats. Liver has the highest pyrazine meta-
bolizing activity although it is likely that all four tissues have 
some activity. Although the values, are rather imprecise, all four 
tissues yielded net activity in every rat tested. 
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TABLE IX 
METABOLISM OF DIMETHYLPYRAZINE BY ORGAN HOMOGENATES 
Organ Specific Activity* 
Liver 1.81 ± .62 
Kidney 0.73 ± .67 
Lung 0.37 ± .15 
Small Intestine 0.56 ± .27 
*Micromoles per gram tissue ± standard deviation. (see p. 23) 
Since liver yielded the highest homogenate activity it was used to 
attempt to localize the subcellular fraction responsible for dimethyl-
pyrazine metabolism. Freshly excised rat liver was fractionated into 
nuclear, mitochondrial, microsomal and soluble supernatent fractions. 
These fractions were then assayed for activity using an incubation pro-
cedure similar to that used for the whole homogenates. No significant 
activities were found in any of the four fractions. These results do 
not necessarily preclude the possibility of the activity residing in a 
particular fraction. Certain necessary conditions may have been 
lacking in the incubations. Cofactor and protein concentrations are 
often very critical for such systems. Some loss of activity may have 
resulted from the long preparation times needed for the fractionation. 
A further fractionation effort utilized the precipitates and 
supernatents from 20 minute centrifugations at 10,000 x g. Significant 
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activity was found in both fractions. The pellet had an activity of 
5.8 nanomoles per mg. protein while the supernatent activity was 8.2. 
Sucrose buffer was found to stabilize the metabolizing system since the 
values for the pellet and supernatent derived from a phosphate buffer 
homogenate were 1.1 and 3,0, respectively. With either buffer the 
10,000 X g supernatent had the larger activity. Like many others this 
metabolizing system could be microsomal. If it is some of the activity 
of the pellet may be due to the presence of unbroken cells. Further 
support for a microsomal system could come from induction experiments 
since some microsomal systems are known to be induced. 
Preparative liver homogenate incubations were used to try to 
determine if the metabolism observed in the tissue homogenate studies 
was due to formation of the same metabolites observed in urine. These 
experiments used SO ml. incubation mixtures containing 10 ml. of liver 
homogenate and the same procedure used in the previous homogenate 
experiments. The final product of the second lyophilization was re-
suspended in 10 ml. deionized water and two ml. samples were chromato-
graphed on 0.6 X 17 em. columns of Dowex 1X8 resin, The eluents were 
15 ml. each of water, 3 N formic acid, 4 N formic acid and 4 N formic 
acid plus 1.0 N ammonium formate and 30 ml. of 4 N formic acid plus 
2.0 N ammonium formate. A consistent reproducible 14C peak was observed 
at tube S-6, although some runs yielded a few scattered peaks between 
tubes 50-80 (Figure 29). The peak at tube six, which eluted at a 
position similar to urinary metabolite fraction one ~as pooled, lyo-
philized and chromatographed on a 1.2 X 45 em. Bio-Gel P-2 column. A 
single radioactive peak was observed (Figure 30). This peak was 
centered at tube 43 and surrounded by high amounts of UV-absorbing 
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material. When the peak was pooled and rechromatographed on P-2 the 
14C peak moved to tube 39 which was close to the eluting position of 
purified fraction Ml, Apparently the large amount of impurities in the 
homogenate fraction caused the compound to elute abnormally late. Thus 
the metabolite formed in the liver homogenates seems at least similar 
to metabolite one of rat urine. The fact that not all of the urinary 
metabolites were observed is not surprising. With disrupted cells, 
essential cofactors might not have been present in sufficient quanti-
ties. Some compounds utilize more than one organ for their metabolism. 
Some pathways involve oxidation in one organ·and conjugation in another. 
G. Induction Studies 
The final in vitro studies were conducted to determine if either 
phenobarbital or dimethylpyrazine can induce the metabolism of di-
methylpyrazine. Induction was monitored by checking liver homogenate 
activities, urinary excretion of metabolites and urinary metabolite 
percentages. Female albino 250 gram rats were injected daily with 
either sodium phenobarbital, dimethylpyrazine or a control solution. 
They were each given 80 mg/kg on day one and 60 mg/kg on days three, 
five, six and seven. The shift to the lower dose was necessitated by 
the severe effects observed on days one and two. On day eight a com-
parison of phenobarbital, dimethylpyrazine and control-injected rats 
was made by checking the dimethylpyrazine-metabolizing activities of 
liver homogenates, The procedure was the same used for the liver 
homogenate experiments. Table X shows the results of an experiment 
using triplicate homogenates from each of two rats from each group. 
Boiled homogenate blanks were also run in triplicate. Phenobarbital 
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produced a significant inductive effect, giving an activity eight times 
that of normal rats. Dimethylpyrazine caused only a marginal increase 
in activity. 
TABLE X 






2,93 ± .41 
0.56 ± .17 
0.35 ± .15 





Two animals from each injection group were used to compare the 
rates of urinary excretion of 14C, Urine was collected for 21 hours 
after injection with 40 mg. of 14C-dimethylpyrazine. Both dimethyl-
pyrazine and phenobarbital caused some increase in urinary 
14C 
excretion (Table XI). Again phenobarbital caused the largest effect, 
yielding a 54% increase in the amount of 14C excreted in the first 21 
hours after injection. It is possible that a shorter sampling time 
than 21 hours would show a greater difference in 
14C excretion but 
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A remaining question was whether the induction caused by pheno-
barbital and dirnethylpyrazine involved selective induction of specific 
pathways. This would be likely to cause an altered ratio of excreted 
metabolites. Aliquots of each of the three 21 hour urine samples were 
chrornatographed in duplicate on 0.6 X 17 ern. Dowex 1X8 columns, using 
the same procedure utilized to obtain the date in Table VIII. The 
results are shown in Table XII. The metabolite percentages are very 
similar in all three urine samples. Metabolite four shows the only 
significant change. 
Induction of microsomal enzymes by foreign compounds is very 
important not only because of the effect on the clearance of these 
compounds but also because microsomal systems also act on other corn-
pounds such as drugs and steroid hormones. Also if the metabolism of 
two compounds is induced by the same inducer then it is likely that 
they are metabolized by the same system. There are apparently two 
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types of inducers. These are the phenobarbital and aromatic hydro-
carbon or 3-methylcholanthrene types. These two systems often oxidize 
the same compound in different positions and probably work by different 
mechanisms (59) . 
TABLE XII 













*Ml, etc. refers to Metabolite One, etc. 








In this study phenobarbital was shown to increase the metabolism 
of dimethylpyrazine both in vivo and in vitro. Thus it is likely that 
dimethylpyrazine is metabolized by a microsomal system. Phenobarbital 
was found to increase the in vitro activity approximately eight-fold. 
This increase is similar to that found by Conney et al. (80). They 
observed an increase in enzyme activity to a maximum of 3-10 times 
normal after three twice daily injections of 40 mg. phenobarbital per 
kilogram. Comparing the results of the control rats in this experiment 
(using females) to the results of the earlier organ homogenate 
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experiments (using males), it is evident that the pyrazine metabolizing 
activity of females is much less than that of males. The male rats had 
an activity of 1.81 ± .62 micromoles/g liver while the rate for females 
was 0.35 ± .15. This was to be expected since adult male rats have 
higher levels of drug metabolizing enzymes. The sex difference in 
metabolizing activity may be the reason why induction is more easily 
observed in female rats (59). Although the females had lower basal 
activity in the present study their level surpassed that of untreated 
males after exposure to phenobarbital. 
CHAPTER V 
SUMMARY 
5,6-14C-2,3-Dimethylpyrazine was synthesized by the condensation 
of ethylenediamine with 2,3-butanedione followed by the catalytic de-
hydrogenation of the resulting dihydro compound. Toxicity studies using 
30-35 gram male albino mice yielded an LD 5 o value of 0.7 mg/g body 
weight. Four metabolites of dimethylpyrazine were isolated from the 
urine of rats. These metabolites were separated using thin layer and 
column chromatographic techniques. Using Dowex 1X8 anion exchange 
resin the same four metabolite peaks were observed in both rat and 
mouse urine. All four metabolites have ultraviolet absorption spectra 
closely resembling that of dimethylpyrazine. This indicates that the 
pyrazine ring has not been cleaved. This is supported by mass spectral 
and NMR studies and also by the fact that both the 2,3-14C and 5,6-
14C-labelled compounds yield the same four metabolite peaks. 
Metabolite one is not strongly anionic while the other three 
metabolites are. Mass spectral studies of metabolite two indicate an 
empirical formula of, C7H9N202. Major fragment ions indicate losses of 
OH, CHO, and C2H402 from the molecular ion. Possible structures for 
metabolite two include 3-methyl-4-(N~methyl)-pyrazinoic acid and 
1-(N-formyl)-2-hydroxymethyl-3-methylpyrazine. Metabolite three is 
apparently a conjugat~ with an alpha-amino acid. Ami~o acid analysis 
of hydrolyzed metabolite three yields a ninhydrin positive peak that 
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elutes between valine and methionine. A possible structure for metabo-
lite three is 2,3-dimethylpyrazine~5-mercapturic acid. The probable 
structure of metabolite four is 3-methylpyrazine-2-carboxylic acid. 
Support for this structure comes from a comparison of the mass spectral 
'and chromatographic properties of metabolite four and pyrazinoic acid. 
Metabolite four fragments by the consecutive losses of 18 and 28 mass 
units. The probable fragmentation pathway is the loss of water via a 
McLafferty rearrangement followed by the loss of a carbonyl group. 
Seventy to eighty per cent of a 50 mg. dose of 14C-dimethylpyrazine 
is excreted in the urine of adult rats in the first 24 hours after 
intraperitoneal injection, Most of the 14C is excreted in the first 12 
hours and very little is excreted after 48 hours. Mice excrete about 
50% of the dose in the first 24 hours. The more anionic metabolites 
are excreted much faster than the less anionic ones in rats. Although 
metabolites two and three are the major metabolites, they are not 
necessarily the most important pharmacologically. Metabolite one is 
excreted at the slowest rate and metabolite four resembles a compound 
known to cause urate retention. After intraperitonial injection di-
methylpyrazine is rapidly cleared from the liver, blood and kidneys of 
~ice. The concentration of 14C peaks in the liver and blood before 20 
minutes and peaks in the kidney at about 40 minutes. 
In vitro tissue homogenate studies showed liver to have the 
largest pyrazine-metabolizing activity when compared to kidney, lung 
and small intestine in rats. Attempts to localize the intracellular 
site of pyrazine metabolism met with little success. The 10,000 X g 
supernatent showed slightly more activity than the pellet. The 
metabolite formed in these tissue homogenates is at least similar to 
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the metabolite number one of urine. 
Both phenobarbital and 2,3-dimethylpyrazine can induce the 
metabolism of dimethylpyrazine. Phenobarbital and dimethylpyrazine 
show approximately eight and two-fold increases in the activities of 
liver homogenates, respectively. Phenobarbital causes a significant 
increase in the amount of 14C excreted after an intraperitoneal dose 
of 14C-dimethylpyrazine while dimethylpyrazine shows a slight increase. 
The induction caused by these two compounds probably does not involve 
a different metabolizing pathway since the metabolite percentages do 
not significantly change. Since pyrazine metabolism is induced by 
phenobarbital it is likely that a microsomal system is involved. 
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